Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST-RCC: Evolocumab and Nivolumab in Metastatic Renal Cell Carcinoma
NCT06284564Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2024; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06284564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284564.